ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome (Q90196273)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

title

ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

Elliott J Brea

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

Aaron Y Chang

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

Tatyana Korontsvit

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

author name string

Claire Y Oh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

Christopher Bourne

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

Tao Dao

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

Megan M Dacek

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

Sung Soo Mun

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

David A Scheinberg

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

publication date

20 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

Cancer Immunology Research

12 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

page(s)

1984-1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

The role of HLA in T cell activation

12 April 2020

cites work

1 reference

12 December 2020

Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line

1 reference

12 December 2020

Transcriptional regulation of HLA-A and -B: differential binding of members of the Rel and IRF families of transcription factors

1 reference

12 December 2020

Kinetically coordinated induction of TAP1 and HLA class I by IFN-gamma: the rapid induction of TAP1 by IFN-gamma is mediated by Stat1 alpha

1 reference

12 December 2020

Inhibition of Stat1-mediated gene activation by PIAS1

1 reference

12 December 2020

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

1 reference

12 December 2020

A new era for cancer immunotherapy based on the genes that encode cancer antigens

1 reference

12 December 2020

Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element

1 reference

12 December 2020

Molecular mechanisms of RET activation in human neoplasia

1 reference

12 December 2020

RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase

1 reference

12 December 2020

HLA class I expression in bladder carcinomas

1 reference

12 December 2020

Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?

1 reference

12 December 2020

Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21.

1 reference

12 December 2020

1 reference

12 December 2020

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells

1 reference

12 December 2020

MAPK-induced Ser727 phosphorylation promotes SUMOylation of STAT1.

1 reference

12 December 2020

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

1 reference

12 December 2020

The Erk2 MAPK regulates CD8 T cell proliferation and survival

1 reference

12 December 2020

Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets

1 reference

12 December 2020

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy

1 reference

12 December 2020

HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank.

1 reference

12 December 2020

CD8 T cell responses against TAP-inhibited cells are readily detected in the human population

1 reference

12 December 2020

Hallmarks of Cancer: The Next Generation

1 reference

12 December 2020

Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes

1 reference

12 December 2020

MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells.

1 reference

12 December 2020

Intracellular Signal Transduction and Modification of the Tumor Microenvironment Induced by RET/PTCs in Papillary Thyroid Carcinoma

1 reference

12 December 2020

Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad

1 reference

12 December 2020

Pathways of antigen processing

1 reference

12 December 2020

Revisiting immune-based therapies for aggressive follicular cell-derived thyroid cancers

1 reference

12 December 2020

Novel targets in non-small cell lung cancer: ROS1 and RET fusions

1 reference

12 December 2020

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

1 reference

12 December 2020

The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer

1 reference

12 December 2020

Ceritinib in ALK-rearranged non-small-cell lung cancer

1 reference

12 December 2020

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL leukemias

1 reference

12 December 2020

Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor

1 reference

12 December 2020

Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein

1 reference

12 December 2020

The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model

1 reference

12 December 2020

ALK inhibitors in non-small cell lung cancer: crizotinib and beyond

1 reference

12 December 2020

Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer

1 reference

12 December 2020

Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation

1 reference

12 December 2020

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.

1 reference

12 December 2020

Neoantigens in cancer immunotherapy.

1 reference

12 December 2020

STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.

1 reference

12 December 2020

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients

1 reference

12 December 2020

ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

1 reference

12 December 2020

TAP-ing into TIEPPs for cancer immunotherapy

1 reference

12 December 2020

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

1 reference

12 December 2020

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.

1 reference

12 December 2020

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.

1 reference

12 December 2020

Targeting neoantigens to augment antitumour immunity

1 reference

12 December 2020

A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.

1 reference

12 December 2020

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

1 reference

12 December 2020

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

1 reference

12 December 2020

Cell Surface MHC Class I Expression Is Limited by the Availability of Peptide-Receptive "Empty" Molecules Rather than by the Supply of Peptide Ligands

1 reference

12 December 2020

ERK is a negative feedback regulator for IFN-γ/STAT1 signaling by promoting STAT1 ubiquitination.

1 reference

12 December 2020

Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.

1 reference

12 December 2020

Identification of non-mutated neoantigens presented by TAP-deficient tumors.

1 reference

12 December 2020

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

1 reference

12 December 2020

Rejection of immunogenic tumor clones is limited by clonal fraction

1 reference

12 December 2020

10.1158/2326-6066.CIR-19-0056

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31540894 AND SRC:MED&resulttype=core&format=json

12 April 2020

1 reference